ICIs specific for checkpoint proteins, such as CTLA-4 or PD-1, have been approved for the treatment of several cancer types, including non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, bladder cancer, and renal cell cancer. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.